Develops treatments for hepatitis B virus (HBV) infection and other autoimmune diseases.
XTL Biopharmaceuticals Ltd., a prominent player in the biopharmaceutical sector based in Ramat Gan, Israel, specializes in acquiring and developing pharmaceutical products tailored to combat autoimmune diseases. At the forefront of its portfolio is hCDR1, a Phase II-ready drug candidate targeting systemic lupus erythematosus (SLE) and Sjogren's syndrome, both complex autoimmune conditions. Through a strategic licensing agreement with Yeda Research and Development Company Limited, XTL Biopharmaceuticals advances the research, development, and potential commercialization of hCDR1 across various therapeutic indications.
Formerly known as Xenograft Technologies Ltd., XTL Biopharmaceuticals underwent a name change in July 1995, reflecting its focused evolution within the biopharmaceutical landscape. Since its inception in 1993, the company has demonstrated a commitment to innovation and therapeutic advancement in autoimmune disorders, leveraging strategic partnerships and a robust research pipeline to drive progress in treatment modalities.
Headquartered in Ramat Gan, Israel, XTL Biopharmaceuticals continues to expand its footprint in the global biopharmaceutical market. With a clear mission to address unmet medical needs and improve patient outcomes, the company remains dedicated to pioneering effective therapies that offer hope and tangible benefits to individuals affected by autoimmune diseases worldwide.